Dermal therapeutic system with high adhesivity

Patent metadata

Field	Value
Publication number	US-9962349-B2
Application number	US-201515519388-A
Country	US
Kind code	B2
Filing date	Oct 15, 2015
Priority date	Oct 17, 2014
Publication date	May 8, 2018
Grant date	May 8, 2018

Abstract

The present invention relates to a high adhesion dermal therapeutic system comprising an adhesive polymeric matrix with a salt of Diclofenac.

First claim

The invention claimed is:

1. A dermal therapeutic system which comprises an adhesive polymeric matrix comprising:
56% by weight with respect to the total dry weight of the adhesive polymeric matrix, of a self-curing acrylate-vinyl acetate copolymer having a Tg lower than 0° C., containing free hydroxyl groups and without free carboxyl groups;
11.1% by weight with respect to the total dry weight of the adhesive polymeric matrix, of a copolymer of dimethylaminoethyl methacrylate, butyl methacrylate, and methyl methacrylate;
13.4% by weight with respect to the total dry weight of the adhesive polymeric matrix, of sodium Diclofenac;
13.4% by weight with respect to the total dry weight of the adhesive polymeric matrix, of polyethylene glycol (12 moles) stearate;
4.5% by weight with respect to the total dry weight of the adhesive polymeric matrix, of sorbitan oleate; and
1.6% by weight with respect to the total dry weight of the adhesive polymeric matrix, of citric acid monohydrate.

2. A dermal therapeutic system which comprises an adhesive polymeric matrix comprising:
54.8% by weight with respect to the total dry weight of the adhesive polymeric matrix, of a self-curing acrylate-vinyl acetate copolymer having a Tg lower than 0° C., containing free hydroxyl groups and without free carboxyl groups;
10.8% by weight with respect to the total dry weight of the adhesive polymeric matrix, of a copolymer of dimethylaminoethyl methacrylate, butyl methacrylate, and methyl methacrylate;
15.3% by weight with respect to the total dry weight of the adhesive polymeric matrix, of Diclofenac diethylammonium salt;
13.1% by weight with respect to the total dry weight of the adhesive polymeric matrix, of polyethylene glycol (12 moles) stearate;
4.4% by weight with respect to the total dry weight of the adhesive polymeric matrix, of sorbitan oleate; and
1.6% by weight with respect to the total dry weight of the adhesive polymeric matrix, of citric acid monohydrate.

3. The dermal therapeutic system according to claim 1 , wherein the adhesive polymeric matrix has a thickness ranging from 50 to 500 microns.

4. The dermal therapeutic system according to claim 1 , further comprising a backing layer and a protective layer.

5. The dermal therapeutic system according to claim 1 , having a surface ranging from 20 to 300 cm 2 .

6. The dermal therapeutic system according to claim 3 , wherein the adhesive polymeric matrix has a thickness ranging from 100 to 350 microns.

7. The dermal therapeutic system according to claim 3 , wherein the adhesive polymeric matrix has a thickness equal to about 300 micron.

8. The dermal therapeutic system according to claim 4 , wherein the backing layer is a 100% polyester non-woven fabric and the protective layer is a siliconized polyester film, a non-woven polyester fabric, or a mono-siliconated glassine paper.

9. The dermal therapeutic system according to claim 5 , having a surface ranging from 100 to about 150 cm 2 .

10. The dermal therapeutic system according to claim 2 , wherein the adhesive polymeric matrix has a thickness ranging from 50 to 500 microns.

11. The dermal therapeutic system according to claim 2 , further comprising a backing layer and a protective layer.

12. The dermal therapeutic system according to claim 2 , having a surface ranging from 20 to 300 cm 2 .

13. The dermal therapeutic system according to claim 10 , wherein the adhesive polymeric matrix has a thickness ranging from 100 to 350 microns.

14. The dermal therapeutic system according to claim 10 , wherein the adhesive polymeric matrix has a thickness equal to about 300 micron.

15. The dermal therapeutic system according to claim 11 , wherein the backing layer is a 100% polyester non-woven fabric and the protective layer is a siliconized polyester film, a non-woven polyester fabric, or a mono-siliconated glassine paper.

16. The dermal therapeutic system according to claim 12 , having a surface ranging from 100 to about 150 cm 2 .

Assignees

• Fidia Farm Spa

Inventors

• Gennari Giovanni
• Zanellato Anna Maria
• Santi Patrizia
• Padula Cristina

Classifications

• A61K47/22

  Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones · CPC title

• A61K9/7061

  Polyacrylates · CPC title

• A61K47/10

  Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers · CPC title

• A61K31/196 Primary

  the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil · CPC title

• A61K47/12

  Carboxylic acids; Salts or anhydrides thereof · CPC title